TALENT: Supraflex Stent Noninferior to Xience

A biodegradable-polymer sirolimus-eluting stent was nonferior to the Xience everolimus-eluting stent in a head-to-head comparison, results of the TALENT trial presented at TCT 2018 suggested.

Researchers for the trial enrolled 1,435 all-comer patients from 23 enrolling sites and randomized them to receive either the Supraflex sirolimus-eluting stent (n=720) compared to the Xience everolimus-eluting stent (n=715). The primary study endpoint for the intent-to-treat analysis was device-oriented cardiovascular events (defined as a composite of cardiac death, target vessel MI, and clinically indicated target lesion revascularization at 12 months.

According to the study results, the rates of device-oriented cardiovascular events at 1 year was 5.3% in the Xience group compared to 4.9% in the Supraflex group (difference: -0.3; 95% CI, -2.6% to 2.0; P=0.801). There was also a 61% relative risk reduction in clinically indicated target lesion revascularization in the Supraflex group compared to Xience (log rank, P=0.021).

“The study results have important economic implications in countries with capped stent prices such as India, and in some European countries with competitive pricing and different models of health care cost savings,” presenter Patrick Serruys, MD, PhD, of the Imperial College of London and Erasmus University, Rotterdam, The Netherlands, noted in a slide from his presentation. “Market competitiveness may influence future decisions on which stent to use.”